Learn
BPC-157 vs TB-500: what each is, what's been studied, and FDA status
By the Everlon founding team · · How we write and review health content
Quick answer BPC-157 and TB-500 are two unrelated lab-made peptides that get talked about as a pair, and neither has much human research behind it. In July 2026 an FDA advisory committee reviewed both, and news reports say it recommended adding each to the list of ingredients pharmacies may compound, against the advice of FDA's own staff. Neither is FDA-approved, and neither is on FDA's 503A bulks list as of October 2026. HHS's draft enforcement-discretion policy, open for public comment and not final, would cover each by its own routes and only as a single active ingredient, so a product combining the two wouldn't be covered.
How do BPC-157 and TB-500 compare?
| What it is | A synthetic peptide of 15 amino acids | A synthetic fragment of 7 amino acids, with an acetyl group added |
|---|---|---|
| Where it comes from | A fragment of a protein first isolated from human gastric juice, per FDA | A piece of thymosin beta-4, a natural protein of 43 amino acids |
| Human studies | Two small, uncontrolled reports from private clinics, plus one exploratory trial known only from a meeting abstract | None found by FDA's reviewers; small trials exist for full-length thymosin beta-4 |
| Use FDA reviewed in 2026 | Ulcerative colitis | Wounds, by injection |
| FDA staff view, July 2026 | Criteria weigh against listing | Criteria weigh against listing |
| Advisory committee, July 23, 2026 (as reported by CNN, July 31, 2026) | Recommended | Recommended |
| Status on October 6, 2026 | Not approved; not on the bulks list; in no FDA category | Not approved; not on the bulks list; in no FDA category |
| HHS's draft policy (open for comment, not final) | Covered in the draft: subcutaneous, intramuscular, oral or topical | Covered in the draft: subcutaneous or intramuscular injection |
What the research measured
Neither peptide has much human research, and the human trials people cite for TB-500 are of a different molecule.
- Most BPC-157 research is preclinical: a 2025 systematic review included 36 studies, and 35 of them were preclinical.
- The human reports on BPC-157 are two small, uncontrolled studies from private clinics in Florida.
- FDA's reviewers found no study in which TB-500 was given to people; small human trials exist only for full-length thymosin beta-4.
BPC-157. The name stands for "body protection compound." A review by the Zagreb group that first made it summarizes their own work, mostly in rats (Sikiric and colleagues, 2011). Independent reviewers noted that the large majority of studies used small rodent models, that only a handful of research groups have studied it in depth, and that its effects remain to be confirmed in people (Gwyer and colleagues, 2019). The 2025 review screened 544 articles, included 36, and found no clinical safety data (Vasireddi and colleagues, 2025).
The two human reports are small. One was a retrospective chart review at a single clinic: of 17 patients who had received knee injections, 16 were reached by phone and asked to rate their own pain, and four of them had also received thymosin beta-4 (Lee and Padgett, 2021). The other followed two adults over three days to look at safety (Lee and Burgess, 2025). Two people over three days cannot show that a substance is safe.
TB-500. Its structure was reported by analytical chemists working on doping control (Esposito and colleagues, 2012), and most peer-reviewed work on the fragment is chemistry of that kind. The full thymosin beta-4 protein has been tested in people, for example as eye drops in a small phase 2 trial of nine people with severe dry eye (Sosne and colleagues, 2015). FDA's reviewers say the protein and the fragment are not the same substance. More on TB-500 is here.
The two together. A 2026 scoping review of six popular peptides found that about two thirds of the publications used animal models and that the few human studies mostly lacked rigorous designs (Tewari and colleagues, 2026). The only study of the pairing found in a PubMed search on October 6, 2026 was in 32 rats; its authors called it exploratory (Biçer and colleagues, 2026).
Full citations are in the Sources list below.
The "Wolverine stack": what the term means
"Wolverine stack" is an online nickname for using BPC-157 and TB-500 together. The name comes from Wolverine, a comic-book character. It is slang, not a medical or regulatory term, and a PubMed search for it returns nothing.
The nickname doesn't change the facts. As of October 2026 neither peptide is on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with. HHS's draft policy would cover each only as a single active ingredient, so a product combining the two wouldn't be covered. FDA's safety statements, quoted in full below, say it lacks the information to know whether either would cause harm in people. No clinical trial of the pairing in people turned up in that search. This page gives no amounts or schedule for either, and doesn't recommend the pairing.
Where both stand with FDA and HHS
Neither BPC-157 nor TB-500 is an FDA-approved drug or, as of October 2026, on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with; FDA removed both from its interim Category 2 on April 22, 2026 after the nominators withdrew their nominations, which FDA's guidance says is not a determination about either substance (how the categories work). In July 2026 FDA's reviewers proposed against adding either to the list, news reports (CNN, July 31, 2026) say the advisory committee voted to recommend both anyway, and only a final rule after notice-and-comment rulemaking would change that, with no proposed rule published as of October 6, 2026 (the full status is here). Since then, HHS has drafted an enforcement-discretion policy that would cover both, each by the routes it lists and under strict conditions; it is not final, it is not approval, and HHS may revisit it (HHS's 2026 draft peptide compounding policy, explained). The National Community Pharmacists Association reported the draft on October 29, 2026. HHS published it as a draft for comment (Federal Register, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; October 30, 2026), with a two-week comment period; the notice says it is "not binding on HHS or the public."
Is this right for me?
Everlon doesn't offer either peptide. Whether any treatment suits you is a decision for a licensed provider who knows your health history, and the answer may be no.
The honest options:
- Use the sign-up at the end of this page if you want availability news. It reserves nothing.
- Bring what's behind the question to your own doctor, who can go over approved treatments.
- Steer clear of "research use only" products; the risks are under Safety information.
- If you compete in tested sport, FDA's briefings note that both appear on the World Anti-Doping Agency's prohibited list.
However the rules change, a licensed provider in your state would still review your health history and decide.
How it works
- Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
- Hear from us only if Everlon offers it. We write about availability and nothing else, and you can unsubscribe anytime.
- A licensed provider still decides. Being on the list is not a reservation or a prescription. If Everlon ever offers it, a provider licensed in your state reviews your health history first and can decline.
FAQ
Are BPC-157 and TB-500 the same thing? No. They are unrelated peptides of different sizes, from different research traditions.
Is either one FDA-approved? No. Neither is an FDA-approved drug, and neither is on the 503A bulks list.
Can a licensed pharmacy combine them? Not under HHS's draft policy, which would cover each only as a single active ingredient. Neither is on FDA's 503A bulks list as of October 2026, and what a final rule would allow depends on the rule FDA writes.
Is the "Wolverine stack" legal? The nickname changes nothing. As of October 2026 neither peptide is on FDA's 503A bulks list or FDA-approved, and HHS's draft policy wouldn't cover the two combined.
What this means for you
As of October 2026, neither BPC-157 nor TB-500 is on FDA's 503A bulks list, the list of ingredients licensed pharmacies may compound with for patients, and only FDA rulemaking changes that. Until a final rule decides, HHS has proposed, in a draft policy, not to take enforcement action against either when its conditions are met; the draft is not final and may change. Compounded medications are not FDA-approved, and products sold online as "research use only" aren't made for people.
HHS's 2026 draft peptide compounding policy, explained covers all six peptides, and the July 2026 FDA peptide vote, explained covers what came before it.
Safety information
There is no FDA-approved, labeled product of either peptide to describe. FDA's safety-risks page says, word for word:
- On BPC-157: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."
- On TB-500: "Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities. FDA has not identified any human exposure data [sic] drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."
Immunogenicity means the risk of an immune reaction. FDA's briefings add that neither substance is well characterized, and that inconsistent naming means a patient could receive a different substance than intended.
Products sold as "research use only" are not prepared by a licensed pharmacy for a named patient, no prescriber reviews your history, and nothing assures you of their identity, purity or sterility. Everlon never sells "research use only" products. Compounded medications are not FDA-approved, including anything compounded under HHS's draft policy.
If you have used a product sold under either name and something feels wrong, stop and contact a doctor; you can also report it to FDA's MedWatch program. If this is a medical emergency, call 911.
Sources
- HHS. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix B; no issue or effective date printed). hhs.gov, accessed 2026-10-29
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-32. PMID: 21548867. PubMed, accessed 2026-10-06
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159. PMID: 30915550. PubMed, accessed 2026-10-06
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485-495. PMID: 40756949. PubMed, accessed 2026-10-06
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13. PMID: 34324435. PubMed, accessed 2026-10-06
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20-24. PMID: 40131143. PubMed, accessed 2026-10-06
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(9):733-8. PMID: 22962027. PubMed, accessed 2026-10-06
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6. PMID: 25826322. PubMed, accessed 2026-10-06
- Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. American Journal of Sports Medicine. 2026 (online ahead of print, August 11). PMID: 42578445. PubMed, accessed 2026-10-06 (abstract only)
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3):822-837. PMID: 42542926. PubMed, accessed 2026-10-06 (abstract only)
- FDA. FDA Briefing Document: BPC-157 (free base) and BPC-157 acetate. Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov, accessed 2026-10-06
- FDA. FDA Briefing Document: TB-500-related bulk drug substances. Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov, accessed 2026-10-06
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-06
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-06
- CNN. FDA advisers support easing restrictions on six peptides. Here's what those drugs are and what happens next. July 31, 2026 (news report). cnn.com, accessed 2026-10-06
Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.
Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.